Shire"s Gaucher disease drug velaglucerase alfa, which was rushed to market a year earlier because of Genzyme Corp.’s manufacturing disruption, could take a 15 percent of the $1.1 billion market by 2012 as well as earning $50 million in 2010. Shire has submitted a safety plan to the FDA allowing the drug to be available whilst Genzyme continues to make its new supply.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지